|
1
|
Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP
and Morris LG: Decision making in the management of recurrent head
and neck cancer. Head Neck. 36:144–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
National Comprehensive Cancer Network
(NCCN), . NCCN Guidelines®. Head and Neck Cancers.
Version 2. NCCN, Plymouth Meeting. (PA). 2019.
|
|
4
|
Yanamoto S, Umeda M, Kioi M, Kirita T,
Yamashita T, Hiratsuka H, Yokoo S, Tanzawa H, Uzawa N, Shibahara T,
et al: Multicenter retrospective study of cetuximab plus
platinum-based chemotherapy for recurrent or metastatic oral
squamous cell carcinoma. Cancer Chemother Pharmacol. 81:549–554.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naruse T, Yanamoto S, Matsushita Y,
Sakamoto Y, Morishita K, Ohba S, Shiraishi T, Yamada SI, Asahina I
and Umeda M: Cetuximab for the treatment of locally advanced and
recurrent/metastatic oral cancer: An investigation of distant
metastasis. Mol Clin Oncol. 5:246–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naruse T, Yanamoto S, Matsushita Y,
Sakamoto Y, Morishita K, Ohba S, Shiraishi T, Yamada SI, Asahina I
and Umeda M: Lower gingival squamous cell carcinoma with brain
metastasis during long-term cetuximab treatment: A case report.
Oncol Lett. 15:7158–7162. 2018.PubMed/NCBI
|
|
7
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hitt R, Irigoyen A, Cortes-Funes H, Grau
JJ, García-Sáenz JA and Cruz-Hernandez JJ; Spanish Head and Neck
Cancer Cooperative Group (TTCC), : Phase II study of the
combination of cetuximab and weekly paclitaxel in the first-line
treatment of patients with recurrent and/or metastatic squamous
cell carcinoma of head and neck. Ann Oncol. 23:1016–1022. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Z, Martin D, Molinolo AA, Patel V,
Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q and Gutkind
JS: mTOR co-targeting in cetuximab resistance in head and neck
cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst.
106:dju2152014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swick AD, Prabakaran PJ, Miller MC, Javaid
AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, et al:
Co-targeting mTORC and EGFR signaling as a therapeutic strategy in
HNSCC. Mol Cancer Ther. 16:1257–1268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rampias T, Giagini A, Siolos S, Matsuzaki
H, Sasaki C, Scorilas A and Psyrri A: RAS/PI3K crosstalk and
cetuximab resistance in head and neck squamous cell carcinoma. Clin
Cancer Res. 20:2933–2946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kozaki K, Imoto I, Pimkhaokham A, Hasegawa
S, Tsuda H, Omura K and Inazawa J: PIK3CA mutation is an oncogenic
aberration at advanced stages of oral squamous cell carcinoma.
Cancer Sci. 97:1351–1358. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ligresti G, Militello L, Steelman LS,
Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA and
Libra M: PIK3CA mutations in human solid tumors: Role in
sensitivity to various therapeutic approaches. Cell Cycle.
8:1352–1358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang YS, Hsu HT, Ko YC, Yeh KT, Chang SJ,
Lin CY and Chang JG: Combined mutational analysis of RAS, BRAF,
PIK3CA, and TP53 genes in Taiwanese patients with oral squamous
cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol.
118:110–116.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S and Mazzucchelli L: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sok MZ, Zavrl M, Greif B and Srpčič M:
Objective assessment of WHO/ECOG performance status. Support Care
Cancer. 27:3793–3798. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishino M, Jackman DM, Hatabu H, Yeap BY,
Cioffredi LA, Yap JT, Jänne PA, Johnson BE and Van den Abbeele AD:
New response evaluation criteria in solid tumors: Revised RECIST
guideline version 1.1. Eur J Cancer. (Suppl 6):S132008.
|
|
19
|
Pinborg JJ, Reichart PA, Smith CJ and van
der Waal I: Histological typing of cancer and precancer of the oral
mucosa. (2nd). (Berlin, Germany). Springer. 1997.
|
|
20
|
Wright JM and Vered M: Update from the 4th
edition of the world health organization classification of head and
neck tumours: Odontogenic and maxillofacial bone tumors. Head Neck
Pathol. 11:68–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bryne M, Boysen M, Alfsen CG, Abeler VM,
Sudbø J, Nesland JM, Kristensen GB, Piffko J and Bankfalvi A: The
invasive front of carcinomas. The most important area for tumour
prognosis? Anticancer Res. 18:4757–4764. 1998.PubMed/NCBI
|
|
22
|
Vis DJ, Bombardelli L, Lightfoot H, Iorio
F, Garnett MJ and Wessels LF: Multilevel models improve precision
and speed of IC50 estimates. Pharmacogenomics. 17:691–700. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jimeno A, Shirai K, Choi M, Laskin J,
Kochenderfer M, Spira A, Cline-Burkhardt V, Winquist E, Hausman D,
Walker L and Cohen RB: A randomized, phase II trial of cetuximab
with or without PX-866, an irreversible oral phosphatidylinositol
3-kinase inhibitor, in patients with relapsed or metastatic head
and neck squamous cell cancer. Ann Oncol. 26:556–561. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Keam B, Kim S, Ahn YO, Kim TM, Lee SH, Kim
DW and Heo DS: In vitro anticancer activity of PI3K alpha selective
inhibitor BYL719 in head and neck cancer. Anticancer Res.
35:175–182. 2015.PubMed/NCBI
|
|
25
|
Munster P, Elkabets M, Gilbert J, Razak
ARA, Ahn MJ, Yen CJ, Lee SH, Wang HM, Herpen C and Lim WT: Abstract
A46: Inhibition of PIK3CA with BYL719 can overcome resistance to
cetuximab in squamous cell carcinoma of the head and neck (SCCHN).
Mol Cancer Ther. 14 (Suppl 7):A46. 2015.
|
|
26
|
Meister KS, Godse NR, Khan NI, Hedberg ML,
Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR and
Duvvuri U: HER3 targeting potentiates growth suppressive effects of
the PI3K inhibitor BYL719 in pre-clinical models of head and neck
squamous cell carcinoma. Sci Rep. 9:91302019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kimura I, Kitahara H, Ooi K, Kato K,
Noguchi N, Yoshizawa K, Nakamura H and Kawashiri S: Loss of
epidermal growth factor receptor expression in oral squamous cell
carcinoma is associated with invasiveness and
epithelial-mesenchymal transition. Oncol Lett. 11:201–207. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmitz S, Bindea G, Albu RI, Mlecnik B
and Machiels JP: Cetuximab promotes epithelial to mesenchymal
transition and cancer associated fibroblasts in patients with head
and neck cancer. Oncotarget. 6:34288–34299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Naruse T, Yanamoto S, Okuyama K, Yamashita
K, Omori K, Nakao Y, Yamada SI and Umeda M: Therapeutic implication
of mTORC2 in oral squamous cell carcinoma. Oral Oncol. 65:23–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
